olaparib

CD274 molecule ; Homo sapiens







7 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 33242536 Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. 2021 Feb 1
2 34082024 ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer. 2021 Sep 28 2
3 34262869 Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial. 2021 1
4 32753881 Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report. 2020 3
5 33336070 A review of current progress in triple-negative breast cancer therapy. 2020 1
6 29680362 Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure. 2018 Jun 1
7 28471727 Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. 2017 Jul 1 1